19 results about "Ephrin" patented technology

The invention relates to the technical field of medicines, and provides a cyclic peptide compound, a pharmaceutical composition and application. The cyclopeptide compound provided by the invention has a structure as shown in a formula I. The cyclopeptide compound has remarkable EphA2 targeting affinity, has remarkable drug development potential on an EphA2 target spot, and has a wide application prospect in diagnosis, prevention and treatment of related diseases with high expression of EphA2. The result of the embodiment shows that the affinity constant KD of the cyclopeptide compound provided by the invention and an EphA2 target is between 1 * 10 <-9 > M and 1 * 10 <-7 > M, the cyclopeptide compound is difficult to dissociate after being combined with the target, and meanwhile, the cyclopeptide compound has very strong competitive capacity for a ligand Ephrin-A1 of the EphA2 target. # imgabs0 #

The present invention relates to new aptamers against EphA2 (ephrin type-A receptor 2), chemically modified versions thereof and / or complexes comprising any thereof, as well as compositions comprising any of these. It further pertains to their use in a method ofEphA2 detection or quantification, or alternatively in a method comprising EphA2 detection or quantification, such as for the screening, diagnosis, prognosis, or monitoring of a EphA2-related disease. It further pertains to the use of the nucleic acid aptamer, complex or composition in a prophylactic and / or therapeutic method for the treatment of a EphA2-related disease, such as EphA2 expressing cancers, including Ewing sarcoma, and to related kits.

The present disclosure relates to ephrin inhibitors, in particular ephrin E inhibitors. In particular, the present disclosure relates to a compound of Formula (A), or a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a salt thereof, or a crystalline form thereof, and uses thereof in the treatment and / or prevention of diseases associated with proinflammatory cell death. (A)

The present invention relates to new aptamers against EphA2 (ephrin type-A receptor 2), chemically modified versions thereof and / or complexes comprising any thereof, as well as compositions comprising any of these. It further pertains to their use in a method ofEphA2 detection or quantification, or alternatively in a method comprising EphA2 detection or quantification, such as for the screening, diagnosis, prognosis, or monitoring of a EphA2- related disease. It further pertains to the use of the nucleic acid aptamer, complex or composition in a prophylactic and / or therapeutic method for the treatment of a EphA2-related disease, such as EphA2 expressing cancers, including Ewing sarcoma, and to related kits.

To provide a novel treatment method for treating organ fibrosis in a subject.SOLUTION: A method for treating organ fibrosis in a subject comprises administering to a subject a therapeutically effective amount of one or more antibodies or antigen binding fragments thereof that bind to and block soluble ephrin-B2 ectodomain.SELECTED DRAWING: None

The present invention relates to novel aptamers directed against EphA2 (Hepatoligand Type A Receptor 2), chemically modified forms thereof and / or complexes comprising any thereof, and compositions comprising any of these. The present invention also relates to their use in methods for detecting or quantifying EphA2, or alternatively, in methods comprising detection or quantification of EphA2, for example for screening, diagnosis, prognosis or monitoring of EphA2-related diseases. The invention also relates to the use of the nucleic acid aptamers, complexes or compositions in prophylactic and / or therapeutic methods for the treatment of EphA2-related diseases, such as EphA2-expressing cancers, including Ewing sarcoma, and to related kits.

Ephrin type receptor tyrosine kinase inhibitors, also known as Eph tyrosine kinase receptor inhibitors, for treating cancer, an inflammatory disease, an autoimmune disease, or a degenerative disease characterized at least in part by the abnormal activity or expression of the Eph receptor tyrosine kinase. The inhibitors are particularly useful for treating certain cancers.

The invention relates to a humanized antibody of a targeted human hepatic ligand protein A receptor 10 and application thereof, the specific antibody of the hepatic ligand protein A receptor 10 (EphA10) or a fragment with immunocompetence of the antibody is specifically combined with the EphA10, and the EphA10 is a very promising target spot for overcoming the drug resistance and resistance of the existing immune checkpoint inhibition factor targeted therapeutic agent. And when an ADC is prepared using the antibody, it is shown that it is capable of specifically killing cancer cells, and thus it is useful as an antibody therapeutic agent for treating cancer using a mechanism that causes cancer cell death by immune cell activation, an antibody therapeutic agent for treating EphA10-expressing cancer, or a cell therapeutic agent for treating EphA10-expressing cancer, and it is useful as an antibody therapeutic agent for treating EphA10-expressing cancer. And can also be used for cancer diagnosis.

The present disclosure relates to an antibody or antigen-binding fragment thereof that is specific to ephrin type-A receptor 10 (EphA10) and a fusion protein containing the antibody or antigen-binding fragment thereof. The present disclosure also relates to a pharmaceutical composition, a method for treating and / or preventing diseases and / or disorders caused by EphA10 in a subject in need, and a method for detecting EphA10 in a sample.

The invention belongs to the technical field of medical biology, and particularly relates to Ephrin-B2 recombinant protein as well as a vaccine, a preparation method and application thereof. In order to treat and prevent fibrotic diseases, the Ephrin-B2 recombinant protein is expressed and purified based on an Ephrin-B2 extracellular fragment, and an adjuvant is added to prepare the Ephrin-B2 recombinant protein vaccine which is used for treating and preventing the fibrotic diseases. Animal experiment results show that the Ephrin-B2 recombinant protein vaccine prepared by the invention can initiate obvious cellular immune and humoral immune response in a mouse body, effectively treat and prevent idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis, and has an obvious inhibitory effect on bleomycin-induced systemic sclerosis skin fibrosis, which can be seen that the Ephrin-B2 recombinant protein vaccine can be used as a vaccine for treating systemic sclerosis skin fibrosis. The Ephrin-B2 recombinant protein and the vaccine thereof provided by the invention provide a candidate scheme for future research on conversion of preventive and therapeutic vaccines for fibrotic diseases.

Provided herein is a method of treating a subject for a glioblastoma, the method comprising: administering to the subject an immune cell genetically modified with: (a) a nucleic acid sequence encoding a binding triggered transcriptional switch (BTTS) that binds to a priming antigen that is tissue-specifically expressed in the central nervous system; (b) a nucleic acid sequence encoding a tandem chimeric antigen receptor (CAR) or T cell receptor (TCR) that has a first binding domain that recognizes Ephrin type-A receptor 2 (EphA2) and a second binding domain that recognizes Interleukin-13 receptor subunit alpha-2 (IL13RA2); and (c) a regulatory sequence operably linked to (b) that is responsive to the BTTS, wherein binding of the BTTS to the priming antigen activates expression of the tandem CAR or TCR, which binds EphA2 and / or IL13RA2 in the glioblastoma and induces killing of glioblastoma cells.

The invention belongs to the technical field of biology, and particularly relates to a composition for improving the developmental potential of oocytes, an in-vitro maturation culture solution and an optimized culture method. And a CCR5 / CXCR3 antagonist. The preparation for in-vitro embryo production contains an Ephrin ligand family and a CCR5 / CXCR3 antagonist, the microenvironment for maturation culture of oocytes is synergistically optimized, further, sesquiterpenol compounds and / or phenylpropane compounds can be added on the basis, and therefore the preparation can be used for preparing the embryos in vitro by means of the synergistic effect of the components. The composition can effectively inhibit the formation of abnormal protein aggregates in oocytes, enhance the ability of proteasomes to remove error protein aggregates, significantly reduce the level of reactive oxygen species (ROS) and increase the content of endogenous antioxidant substances such as glutathione (GSH), so as to reduce the protein toxicity stress, oxidative stress and other dimensions, and thus, the composition can be used for preparing an anti-inflammatory drug. The quality and the fertilization rate of oocytes after in-vitro maturation and the development potential of subsequent embryos are remarkably improved, and the application prospect is wide.

The present invention relates to an antibody specifically binding to human L1CAM for use in the treatment or prevention of human L1CAM positive hematological malignancy disease in a human subject; and a pharmaceutical composition, kit or cartridge kit comprising (i) an antibody that specifically binds to human L1CAM, and (ii) an active compound selected from the group consisting of a Bcl-2 inhibitor, a BCR / Abl tyrosine kinase inhibitor, a Src tyrosine kinase inhibitor, a c-Kit tyrosine kinase inhibitor and / or a hepatic ligand protein receptor tyrosine kinase inhibitor and an HDAC inhibitor; and related uses and methods.

Provided herein are radiopharmaceutical conjugate compositions that target EphA2 and uses thereof. In one aspect, provided herein are conjugates comprising a peptide having affinity for EphA2 and a metal chelating agent configured to bind to a radionuclide. The conjugates described herein may further comprise a linker linking the chelating agent and the peptide. The conjugates described herein may further comprise radionuclides. In another aspect, provided herein are conjugates comprising a peptide having affinity for EphA2 and a covalently bound radionuclide. The conjugates described herein may further comprise a linker linking the radionuclide and the peptide. Further provided herein are methods of treating cancer by administering the conjugates and compositions.

The invention belongs to the technical field of biology, and particularly relates to a preparation for in-vitro embryo production, a culture medium and application thereof, and the preparation contains the following components: an Ephrin ligand family. The preparation for in-vitro embryo production contains the Ephrin ligand family and can effectively improve the in-vitro maturation quality and development efficiency of oocytes, and further, a flavonoid compound can be added on the basis, so that the preparation can be used for improving the in-vitro maturation quality and development efficiency of the oocytes through the synergistic effect of the Ephrin ligand family and the flavonoid compound. The invention has the advantages that the effects of enhancing mitochondrial function and ATP (adenosine triphosphate) synthesis capability, removing reactive oxygen species (ROS), reducing DNA (deoxyribonucleic acid) damage and spindle abnormality rate, inhibiting proinflammatory factor expression and NF [kappa] B signal channel activity and the like are exerted, so that the in-vitro maturation quality and embryonic development potential of the oocyte are obviously improved, and the application prospect is wide.